What changed
$MET — ADD 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $19.1B | EPS $2.42 vs $2.27 🟢
💡 Market treats the beat as one-time due to volatile investment gains, but segment growth and high rates imply earnings base is higher, leading to upward revisions and P/E expansion from low levels.
📉 Reward/risk: 2.9:1
🏢 Business Quality: 7/10 - Leading diversified insurer with scale, capital return, and improving ROE, but mature industry and interest rate sensitivity.
📊 Valuation: fair to cheap - trailing P/E ~8.9x vs. historical 8-12x, discount to peers; attractive FCF yield and robust buyback support.
🔮 Catalyst: Upcoming Q2 2026 earnings in July; new analyst reports post-Q1 may raise targets
💰 Entry: $85.85, stop $82.0, target $97.0
⚖️ Add MetLife on post-earnings beat and low multiple with upward estimate revisions catalyst.
📊 Our read: ADD. Full analysis →
https://stockduty.xyz/s/MET0618